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Supporting research 
leadership in Africa
The Editorial published in The Lancet 
Global Health and The Lancet Diabetes 
and Endocrinology by Davies and 
Mullan1,2 spotlighted Africa’s need to 
build local health research capacity. 
Parachuting in research solutions 
from developed countries doesn’t 
work: “African researchers are best 
placed to ask questions that are relevant 
to African issues.”1 Withdrawal of 
support from the Wellcome Trust 
and PEPFAR is a major setback for 
research development in Africa. 
Additional challenges include the 
need to develop multidisciplinary 
research team approaches, bridge 
the knowledge translation gap, and 
ﬁ nd local sustainable African research 
leadership. But can all of this be done 
at reasonable cost? 
MicroResearch, modelled on 
microﬁ nance, is an innovative African/
Canadian research partnership, 
which was launched in 2008. The 
project is aimed at building local 
health-care professionals’ capacity 
to find solutions for community 
maternal and child health problems 
by: (1) training multidisciplinary local 
teams to identify health problems; 
(2) coaching teams to develop their 
question into a scientiﬁ cally rigorous 
research proposal; (3) after local 
ethics approval, providing small funds 
(CAN$2000); (4) coaching teams to 
conduct the project and translating 
findings into action; (5) sharing 
findings through publication and 
forums; and (6) growing local 
MicroResearch African leadership.3
By 2016, 27 workshops were 
completed with more than 
700 African health professionals 
trained, 50 team proposals launched, 
22 completed, and 22 publications, 
all in a gender equitable manner. 
Several MicroResearch projects have 
already led to local programme and 
policy changes.3 All of this has been 
achieved for less than CAN$500 000. 
Thus, building research capacity for 
health-care worker teams to ﬁ nd local 
solutions that ﬁ t culture, context, and 
resources, can be done at low cost. 
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I read your Editorial published in 
The Lancet Global Health (May, 
2016)1 and The Lancet Diabetes and 
Endocrinology2 with some surprise. 
It is unfortunate that you neglected 
to mention that the Wellcome Trust 
has recently greatly increased its 
commitment to building research 
capacity in Africa.
In 2014, we reviewed our funding 
in Africa with the intention of 
expanding our support. Since then 
we have launched DELTAS Africa, in 
partnership with the UK’s Department 
for International Development (DFID).3 
DELTAS Africa is a £60 million scheme 
over 5 years through which we will fund 
11 consortia and expect to train up to 
2000 African researchers.4 This activity 
is in addition to our major programmes 
in Kenya, Malawi, and South Africa, the 
Human Hereditary and Health (H3A 
Africa) programme, and Global Health 
Trials, which together total more than 
£230 million of current investment. 
At the same time, with our partners 
at the UK Department for International 
Development and the Bill & Melinda 
Gates Foundation, we are establishing 
and investing in the Alliance for 
Accelerating Excellence in Science in 
Africa (AESA), the ﬁ rst and only pan-
African funding platform whose sole 
aim is to strengthen research capacity. 
With the establishment of AESA, 
we signal a real shift in the centre of 
gravity of leadership and eventually 
funding of African science to Africa.
Competition from excellent 
programmes led by African researchers 
continues to grow, and while 
inevitably this means that some 
will not be successfully funded, it is 
a sure sign of a ﬂ ourishing research 
environment.
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For more on KEMRI-Wellcome 
Trust Research Programme see 
http://kemri-wellcome.org/
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For more on the Africa Centre 
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GADA persistence and 
diabetes classiﬁ cation
We warmheartedly support the call 
of Shazhan Amed and Paolo Pozzolli 
in their Comment1 in The Lancet 
Diabetes & Endocrinology for optimising 
diagnostic accuracy in children and 
adolescents at onset of diabetes. 
Measurement of antibodies at onset 
would definitely contribute to the 
proper classiﬁ cation and treatment of 
diabetes in young patients. Despite 
